Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
Gupta
A K
AK
Department of Medicine, Sunnybrook and Women's College Health Sciences Center, University of Toronto, Ontario, Canada. agupta@execulink.com
Lambert
J
J
D000284:Administration, Oral; D000935:Antifungal Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D017850:Economics, Pharmaceutical; D015725:Fluconazole / Q000627:therapeutic use; D005533:Foot Dermatoses / Q000188:drug therapy*; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy*; D000077291:Terbinafine; D014481:United States
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D006118:Griseofulvin; D015725:Fluconazole; D000077291:Terbinafine